Brief: AstraZeneca Says Enhertu Recommended For EU Approval For Early Breast Cancer
21/09/2026 07:22
BRIEF-AstraZeneca Says Enhertu Recommended For EU Approval For Early Breast Cancer Sept 21 (Reuters) - AstraZeneca PLC AZN.L:
ASTRAZENECA PLC - ENHERTU RECOMMENDED FOR APPROVAL IN EU IN EARLY BC
ASTRAZENECA - CHMP RECOMMENDS ENHERTU FOR APPROVAL IN EU AS ADJUVANT TREATMENT FOR HER2-POSITIVE EARLY BREAST CANCER
Source text: ID:nRSU4421Va
Further company coverage: AZN.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AstraZeneca
See all newsAstraZeneca says FDA approves drug for rare kidney disease in adults
AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial
Early US flu season, current strain may signal risk for younger people; doctors urge shots
AstraZeneca partners with Oracle for AI-driven clinical trials
Factbox: Pharma sector doubles down on AI to slash costs, timelines